Pharma & Biotech

Iovance Biotherapeutics finds itself at a critical juncture as it prepares for significant investor conferences in early September. These events...

Pharmaceutical giant Eli Lilly, already reaping billions from its revolutionary weight-loss and diabetes treatments, may be on the verge of...

Cardiff Oncology enters a crucial period with three major investor conferences scheduled for early September, providing the biotechnology firm with...

Sarepta Therapeutics finds itself at a pivotal crossroads as it transitions from the S&P MidCap 400 to the S&P SmallCap...

Biotech firm Replimune confronts a pivotal moment for its future as it engages in a decisive Type-A meeting with U.S....

Axsome Therapeutics finds itself navigating a complex landscape as generic manufacturer Apotex Inc. launches a legal challenge against the market...

A significant regulatory milestone in Europe has positioned Abbott Laboratories for accelerated growth within its structural heart business. The medical...

Johnson & Johnson is demonstrating robust performance across its two primary business segments. The company's oncology franchise is being powered...

Gilead Sciences appears to be on the cusp of a significant transformation. The biotechnology firm's stock is exhibiting robust technical...

The biotechnology giant Amgen finds itself navigating a complex landscape where groundbreaking innovation collides with mounting competitive pressures. While the...